Apellis Pharmaceuticals Inc (APLS) Directors and Executive Officers

Officers & Directors

A. Sinclair Dunlop
Director

Timothy E. Sullivan
Chief Financial Officer and Treasurer (Principal Financial Officer)

Alec Machiels
Director

Paul Fonteyne
Director

Stephanie M. O Brien
Director

Jim Chopas
Vice President, Corporate Controller and Chief Accounting Officer (Principal Accounting Officer)

Gerald Chan
Director

Cedric Francois
President, Chief Executive Officer and Director (Principal Executive Officer) ,

Apellis Pharmaceuticals Inc currently has 739 employees.

News about Apellis Pharmaceuticals Inc Key Personnel

Apellis Pharmaceuticals' Strategic Equity Inducement Awards Ignite Growth PotentialExplanation: This title emphasizes the proactive and calculated approach of Apellis Pharmaceuticals in bolstering its workforce and setting the stage for enhanced growth opportunities. It signifies the positive trajectory the company is embarking upon by aligning employee interests with long-term success.

Apellis Pharmaceuticals, a leading global biopharmaceutical company specializing in complement, recently announced the approval of equity awards for several new employees. These equity awards, granted under Nasdaq Listing Rule 5635(c)(4) and falling under the terms of the 2020 Inducement Stock Incentive Plan, serve as an indispensable factor in attracting and securing top talents.
Impact on the Company:
Apellis Pharmaceuticals has recorded a cumulative net loss of $-606 million during the 12 months ending in the third quarter of 2023, reflecting a negative return on assets (ROA) of -71.1%. However, inspite of these financial challenges, the company has taken a bold step in strengthening its...

Apellis Pharmaceuticals Faces Obstacles as CHMP Gives Negative Opinion on Pegcetacoplan for GA Treatment in EU; Planned Re-Examination to Determine Future

By
Date: Today s Date
WALTHAM, Mass. - Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) received a blow to its plans for the marketing authorization of intravitreal pegcetacoplan in the European Union (EU) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a negative opinion on the company s application, putting a halt to Apellis Pharmaceuticals progress in the EU market.
This news does not come as a surprise, as a negative trend vote was anticipated after an oral explanation meeting held in December 2023. However, Apellis Pharmaceuticals...